More Videos
- Predictions: 9 For '09 In Pharma
- Johnson & Johnson Is Latest FDA Casualty
- Genentech: Roche Says One Thing, Investors Say Another
- Schering-Plough: The Reviews Are In
- Pharma Updates And What You Need To Know
- The Emails Fly On GM, Ford CEO's Corporate Jets
- Merck Offering To Help Patients—Or Itself?
- GM, Ford & Chrysler CEOs Take Their Medicine
- Daschle's Dollars From Lawyers, Not Pharma
- AstraZeneca Provides Zest and Zeal For OSI Pharmaceuticals
- Cramer's Outrage: Paulson & Bernanke
- Lightning Round: Genzyme, Goldman Sachs, U.S. Steel and More
- Lightning Round OT: Verizon, Kroger, Novartis and More
- Executive Decision: Foster Wheeler CEO Ray Milchovich
- Cavs Owner Doesn't Mind Buzz Over James
- Trading Obama's Stimulus Plan
- What Bailouts?
- Your First Move For Tuesday December 2nd
- Web Extra: Fast & Furious Trades For Tuesday
- Australia Cuts Rates to 6-½ Year Low, May Cut Again
- Toyota to Cut Bonuses Amid Reports of Output Cuts
- China Eyes Consumer Boost, May Aim 8% 2009 Growth
- Australia Retail Sales Rise No Bar to Sharp Rate Cut
- Asia Slides on Economic Woes, Nikkei Slumps 6.4%
- Beyond Rate Cuts: Other Fed Tools Against Downturn
- Paulson's Speech on the Economy and Financial System
- Paulson: US Weighs Other Uses for the Bailout Fund
- House Democrats May Seek $500 Billion Stimulus
Text Size 
 |
Besides cost-cutting, the weak dollar has been propping up revenue and profits during a time when the sector is battling intense competition from much cheaper generic drugs, safety and regulatory issues, drug development pipeline challenges and disappointments, etc.
But given the recent strength in the greenback, Deutsche Bank analyst Barbara Ryan says the sector may not be able to rely on forex for very much longer.
On Tuesday, she put out a research note to clients entitled, "When does the tailwind become a headwind?" Ryan believes that if current trends hold up, then the exchange rate upside will go down the rest of this year and may go away next year.
More on The Dollar: |
But she thinks that the industry's ongoing expense reductions could absorb the dollar's potential impact on the bottom line. Ryan says the biggest beneficiaries of the weak dollar have been Schering-Plough [SGP
Loading...
()
] and Pfizer [PFE
Loading...
()
], because they sell a bigger percentage of their drugs overseas than their competitors.
And speaking of Pfizer, I may have spoken too soon yesterday about PFE shares leaving the teens: The stock couldn't hang on and closed below 20. I'm guessing technical analysts might be able to dissect what's going on. If you've got a logical explanation, please send it here.
Anyway, today PFE has touched the 20-dollar level again -- but is struggling to stay there.
Questions? Comments?
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes